Chronic schizophrenia

Preview

Perhaps one fourth of patients with schizophrenia respond only partially to standard neuroleptic therapy. Until recently, the only pharmacologic option for such patients was adjunctive treatment with other psychotropic drugs. Now two newer drugs—clozapine and risperidone—offer hope to patients with treatment-resistant schizophrenia. This article provides an up-to-date look at effective treatment of this troubling disorder.

Additional information

Notes on contributors

Raymond Pary

Raymond Pary, MD Carmelita R. Tobias, MD Steven Lippmann, MD Dr Pary (right) and Dr Tobias (left) are associate professors, department of psychiatry and behavioral sciences, University of Louisville School of Medicine, and staff psychiatrists, Veterans Affairs Medical Center, Louisville. Dr Lippmann (not pictured) Is professor, department of psychiatry and behavioral sciences, University of Louisville School of Medicine.

Carmelita R. Tobias

Raymond Pary, MD Carmelita R. Tobias, MD Steven Lippmann, MD Dr Pary (right) and Dr Tobias (left) are associate professors, department of psychiatry and behavioral sciences, University of Louisville School of Medicine, and staff psychiatrists, Veterans Affairs Medical Center, Louisville. Dr Lippmann (not pictured) Is professor, department of psychiatry and behavioral sciences, University of Louisville School of Medicine.

Steven Lippmann

Raymond Pary, MD Carmelita R. Tobias, MD Steven Lippmann, MD Dr Pary (right) and Dr Tobias (left) are associate professors, department of psychiatry and behavioral sciences, University of Louisville School of Medicine, and staff psychiatrists, Veterans Affairs Medical Center, Louisville. Dr Lippmann (not pictured) Is professor, department of psychiatry and behavioral sciences, University of Louisville School of Medicine.